Kenya recalls three widely used drugs over safety concerns

Kenyas Pharmacy Board issues urgent recall of several substandard medications

KENYA – The Pharmacy and Poisons Board (PPB) of Kenya has issued a critical alert, recalling multiple batches of commonly used medications due to quality concerns and potential health risks. ​

Paracetamol injections exhibiting discoloration

Three batches of paracetamol 1000mg/100ml injections have been identified as substandard, showing signs of discoloration that may indicate compromised quality. The affected products include: ​

MedExpo Africa 2025
  • Lumidol Injection: Batch Numbers CM4594007, CM4594008, CM4594009​
  • Blink Injection: Batch Numbers CS4594005, CS4594004​
  • Paragen Injection: Batch Number K4290027​

All these injections were manufactured by KamlaAmrut Pharmaceutical in India. The PPB advises immediate cessation of their use and distribution. ​

S-Prazo capsules contaminated with incorrect medication

A batch of S-Prazo (Esomeprazole 40mg) capsules, used to treat acid-related stomach issues, has been recalled following reports of packaging errors.

Batch No. SPZ404 was found to contain Levofloxacin 500mg tablets instead of the intended esomeprazole capsules.

This mix-up poses significant health risks due to potential incorrect dosing and adverse reactions. ​

Falsified Augmentin batches detected

The PPB has also identified falsified batches of the antibiotic Augmentin in the Kenyan market. The affected batches are: ​

  • Augmentin 1G: Batch Number SHS2​
  • Augmentin 625MG: Batch Numbers 8X3K and EU7C​

These counterfeit medications may not provide the intended therapeutic effects and could contribute to antibiotic resistance. ​

Public advisory and reporting

PPB CEO Fred Siyoi urges all pharmaceutical outlets, healthcare providers, and the public to: ​

  • Immediately stop the distribution, sale, and use of the specified batches. ​
  • Return any remaining stock to the nearest healthcare facility or supplier. ​
  • Report any adverse drug reactions or cases of substandard medicines to the PPB through their official channels. ​